Get the Stockscreener App
6.06
2.89%
0.17
After Hours:
6.12
0.06
+0.99%
89 Bio Inc stock is traded at $6.06, with a volume of 1.02M.
It is up +2.89% in the last 24 hours and down -30.34% over the past month.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
See More
Previous Close:
$5.89
Open:
$5.85
24h Volume:
1.02M
Relative Volume:
0.41
Market Cap:
$864.23M
Revenue:
-
Net Income/Loss:
$-174.61M
P/E Ratio:
-3.0761
EPS:
-1.97
Net Cash Flow:
$-165.54M
1W Performance:
+21.32%
1M Performance:
-30.34%
6M Performance:
-26.19%
1Y Performance:
-33.84%
1-Day Range:
$5.76
$6.11
1-Week Range:
$4.90
$6.1252
52-Week Range:
$4.16
$11.84
89 Bio Inc Stock (ETNB) Company Profile
Name
89 Bio Inc
Sector
Industry
Phone
(415) 432-9270
Address
142 SANSOME STREET, SAN FRANCISCO, CA
Compare ETNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
6.06 | 864.23M | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Resumed | BofA Securities | Buy |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-10-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-23 | Initiated | UBS | Buy |
| Jun-13-23 | Initiated | Evercore ISI | Outperform |
| May-12-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-20 | Initiated | Raymond James | Strong Buy |
| Sep-25-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-23-20 | Initiated | BTIG Research | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Dec-09-19 | Initiated | BofA/Merrill | Neutral |
| Dec-09-19 | Initiated | Oppenheimer | Outperform |
| Dec-09-19 | Initiated | RBC Capital Mkts | Outperform |
| Dec-09-19 | Initiated | SVB Leerink | Outperform |
View All
89 Bio Inc Stock (ETNB) Latest News
89bio: A Buy With Strong Market Opportunity In MASH And SHTG - Seeking Alpha
89bio’s chief technical operations officer sells $91,207 in stock By Investing.com - Investing.com India
89bio’s chief technical operations officer sells $91,207 in stock - Investing.com
89bio: Primary Asset Targeting 2 Potential Indications; In Late-Stage Development (ETNB) - Seeking Alpha
Vanguard Group Inc. Grows Stock Holdings in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio, Inc. (NASDAQ:ETNB) Shares Bought by Wellington Management Group LLP - Defense World
89bio, Inc. (NASDAQ:ETNB) Shares Bought by American Century Companies Inc. - Defense World
Corebridge Financial Inc. Sells 3,141 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio, Inc. (NASDAQ:ETNB) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
KLP Kapitalforvaltning AS Purchases New Holdings in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio (NASDAQ:ETNB) Receives Sell (D-) Rating from Weiss Ratings - Defense World
Looking For A Good Stock? Let This 89bio Inc (NASDAQ: ETNB) Analysis Help. - stocksregister.com
89bio stock hits 52-week low at $5.96 amid market challenges - Investing.com Canada
89bio stock hits 52-week low at $5.96 amid market challenges By Investing.com - Investing.com South Africa
Teacher Retirement System of Texas Has $191,000 Holdings in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Swiss National Bank Grows Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Certain Warrants of 89bio, Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2025. - MarketScreener
Raymond James Financial Inc. Invests $2.95 Million in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Certain Options of 89bio, Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2025. - marketscreener.com
Are 89bio Inc (NASDAQ: ETNB) Analysts Predicting A Spike? - Stocks Register
Victory Capital Management Inc. Acquires 1,437 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
PNC Financial Services Group Inc. Increases Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio (NASDAQ:ETNB) Given Sell (D-) Rating at Weiss Ratings - Defense World
89bio, Inc. (NASDAQ:ETNB) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $27.56 Average Target Price from Analysts - Defense World
89bio, Inc. (NASDAQ:ETNB) Shares Sold by Steward Partners Investment Advisory LLC - Defense World
89bio (NASDAQ:ETNB) Research Coverage Started at The Goldman Sachs Group - Defense World
Citigroup Initiates Coverage on 89bio (NASDAQ:ETNB) - Defense World
Goldman Sachs starts 89bio stock with neutral, $11 target By Investing.com - Investing.com Australia
Goldman Sachs Initiates Coverage of 89bio (ETNB) with Neutral Recommendation - Nasdaq
Goldman Sachs Initiates Coverage on 89bio With Neutral Rating, $11 Price Target -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Goldman Sachs starts 89bio stock with neutral, $11 target - Investing.com India
89bio initiated with a Neutral at Goldman Sachs - TipRanks
Commit To Buy 89bio At $7.50, Earn 25.1% Annualized Using Options - Nasdaq
Citigroup Initiates Coverage of 89bio (ETNB) with Buy Recommendation - Nasdaq
Citigroup Initiates 89bio Inc at Buy With $25 Price Target -March 13, 2025 at 07:13 am EDT - Marketscreener.com
89bio initiated with a Buy at Citi - TipRanks
Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now - Yahoo Finance
Time nigh for I&I? Key data points ahead - BioWorld MedTech
89bio Inc (NASDAQ: ETNB) Is On The Fall - Stocks Register
89bio (NASDAQ:ETNB) Earns Sell (D-) Rating from Weiss Ratings - Defense World
Rhumbline Advisers Has $1.02 Million Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
MASH field still hot as Boehringer axes $870M deal with Yuhan - BioWorld MedTech
89bio FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Boston Pharma Plays Catch Up To Akero, 89bio In MASH - Citeline News & Insights
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
New York State Common Retirement Fund Has $128,000 Stake in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio to Participate in the Leerink Partners Global Healthcare Conference - The Manila Times
Can 89bio's Liver Disease Pipeline Impress Investors at Upcoming Leerink Conference? - StockTitan
Cantor maintains Overweight on 89bio stock, price target at $29 - Investing.com
Cantor maintains Overweight on 89bio stock, price target at $29 By Investing.com - Investing.com UK
89 Bio Inc Stock (ETNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):